Merck Highlights New Data for Evobrutinib, First BTKi to Demonstrate Sustained Clinical Benefit for People with RMS through Three and a Half Years of Treatment
DARMSTADT, Germany -- (BUSINESS WIRE) -- Merck, a leading science and technology company, today announced findings which demonstrated that annualized relapse rates (ARR) remained low and Exp......
